ArticleiScience2026
Rheumatoid arthritis burden in 129 low- and middle-income countries from 1990 to 2023.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Co-recorded conditions in ischemic and hemorrhagic stroke: a 20-year national analysis of 598,186 natural deaths with machine learning.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) causes substantial disability in low- and middle-income countries (LMICs), which account for most of the global population. Using Global Burden of Disease (GBD) 2023 data, we assessed RA prevalence, incidence, mortality, and disability-adjusted life-year (DALY) rates across 129 LMICs from 1990 to 2023 and projected trends to 2050. Countries were stratified by gross national income (GNI) into low-income, lower-middle-income, and upper-middle-income groups. In 2023, RA affected 12.6 million individuals, with prevalence in upper-middle-income countries being 4.1-fold higher than in low-income countries. Death rates converged across income groups, while absolute inequality in prevalence widened and inequality in mortality narrowed. Projections to 2050 indicated declining mortality in low-income settings but increasing in middle-income countries. Therefore, it is necessary to improve diagnostic capacity in low-income settings and medication affordability in middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.